TD Asset Management
GENB icon

TD Asset Management’s Generate Biomedicines GENB Stock Holding History

TD Asset Management’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.78M Buy
180,000
+129,252
+255% +$1.99M ﹤0.01% 898
2026
Q2 		$856K Buy
50,748
+7,882
+18% +$107K ﹤0.01% 1115
2026
Q1 		$536K Buy
+42,866
New +$523K ﹤0.01% 1165

Other funds holding GENB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Davern Capital Partners
Davern Capital Partners Ny, New York $514M AUM 16.9% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

TD Asset Management's GENB Position: Q3 2026 in Review

TD Asset Management increased its Generate Biomedicines (GENB) stake by 255% in Q3 2026, buying an estimated $1.99M and bringing the position to 180,000 shares worth $2.78M. The position accounts for ﹤0.01% of the portfolio, ranked #898.

TD Asset Management first reported a position in GENB in Q1 2026 and has held it in 3 quarters since. 71 funds tracked by Wall St. Rank hold GENB as of Q3 2026.

  • TD Asset Management held 180,000 shares of Generate Biomedicines worth $2.78M as of Q3 2026.
  • TD Asset Management bought 129,252 Generate Biomedicines shares in Q3 2026, an estimated $1.99M.
  • Generate Biomedicines made up ﹤0.01% of TD Asset Management's portfolio in Q3 2026, its #898 holding.
  • TD Asset Management first reported a position in Generate Biomedicines in Q1 2026 and has held it in 3 quarters since.
  • 71 funds tracked by Wall St. Rank held Generate Biomedicines as of Q3 2026.

Based on TD Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.